Spq Asia Capital Ltd adds China Biologic Products Inc (CBPO) to its portfolio

China Biologic Products Inc (CBPO) : Spq Asia Capital Ltd added new position in China Biologic Products Inc during the most recent quarter end. The investment management firm now holds 32,000 shares of China Biologic Products Inc which is valued at $4,020,480 , the company said in a statement filed on Aug 15, 2016 with the SEC.China Biologic Products Inc makes up approximately 4.32% of Spq Asia Capital Ltd’s portfolio.

Other Hedge Funds, Including , Ahl Partners Llp sold out all of its stake in CBPO during the most recent quarter. The investment firm sold 7,289 shares of CBPO which is valued $915,790.Matthews International Capital Management reduced its stake in CBPO by selling 60,454 shares or 64.34% in the most recent quarter. The Hedge Fund company now holds 33,500 shares of CBPO which is valued at $4,208,940. China Biologic Products Inc makes up approx 0.17% of Matthews International Capital Management’s portfolio.

China Biologic Products Inc opened for trading at $110 and hit $111.9 on the upside on Thursday, eventually ending the session at $110.57, with a gain of 0.48% or 0.53 points. The heightened volatility saw the trading volume jump to 3,48,703 shares. Company has a market cap of $2,974 M.

On the company’s financial health, China Biologic Products Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.08 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $1.18. The company had revenue of $91.42 million for the quarter, compared to analysts expectations of $87.58 million. The company’s revenue was up 15.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.06 EPS.

China Biologic Products Inc. (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research development manufacturing and sales of human plasma-based biopharmaceutical products in China. China Biologic has a product portfolio with over 20 different dosage forms of plasma products. The Company’s principal products are human albumin and immunoglobulin for intravenous injection (IVIG). China Biologic operates its business through two subsidiaries namely Shandong Taibang Biological Products Co. Ltd. and Guizhou Taibang Biological Products Co. Ltd. The Company also holds an interest in Xi’an Huitian Blood Products Co. Ltd. a plasma products company. Its products include human albumin human immunoglobulin IVIG thymopolypeptides injection human hepatitis B immunoglobulin human rabies immunoglobulin human tetanus immunoglobulin placenta polypeptide Factor VIII and human prothrombin complex concentrate (PCC).

Leave a Reply

China Biologic Products Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on China Biologic Products Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.